Fournier’s Gangrene and Sodium-Glucose Cotransporter-2 Inhibitors: Is There a Causal Association?

Journal of Diabetes - United States
doi 10.1111/1753-0407.12897
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2017English

Heart Failure Prevention With Sodium‐glucose Cotransporter 2 Inhibitors

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Effects of Sodium Glucose Cotransporter Type 2 Inhibitors on Heart Failure

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2015English

Erratum To: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Cardiology and Therapy
2016English

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2019English

Differential Cardiovascular Profiles of Sodium-Glucose Cotransporter 2 Inhibitors: Critical Evaluation of Empagliflozin

Therapeutics and Clinical Risk Management
2017English

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy